JP2009508521A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009508521A5 JP2009508521A5 JP2008532177A JP2008532177A JP2009508521A5 JP 2009508521 A5 JP2009508521 A5 JP 2009508521A5 JP 2008532177 A JP2008532177 A JP 2008532177A JP 2008532177 A JP2008532177 A JP 2008532177A JP 2009508521 A5 JP2009508521 A5 JP 2009508521A5
- Authority
- JP
- Japan
- Prior art keywords
- vhh
- antigen
- protein
- carrier
- specific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims 21
- 102000036639 antigens Human genes 0.000 claims 21
- 108091007433 antigens Proteins 0.000 claims 21
- 108090000623 proteins and genes Proteins 0.000 claims 17
- 238000000034 method Methods 0.000 claims 13
- 102000004169 proteins and genes Human genes 0.000 claims 13
- 230000027455 binding Effects 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 239000000969 carrier Substances 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 238000012216 screening Methods 0.000 claims 4
- 238000004220 aggregation Methods 0.000 claims 3
- 230000002776 aggregation Effects 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 241000288906 Primates Species 0.000 claims 2
- 230000009870 specific binding Effects 0.000 claims 2
- 238000012360 testing method Methods 0.000 claims 2
- HCHFRAXBELVCGG-JYFOCSDGSA-N (2z,3z)-2,3-bis[(4-methoxyphenyl)methylidene]butanedinitrile Chemical compound C1=CC(OC)=CC=C1\C=C(/C#N)\C(\C#N)=C\C1=CC=C(OC)C=C1 HCHFRAXBELVCGG-JYFOCSDGSA-N 0.000 claims 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 1
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 1
- 102100034239 Emerin Human genes 0.000 claims 1
- HCHFRAXBELVCGG-UHFFFAOYSA-N Emerin Natural products C1=CC(OC)=CC=C1C=C(C#N)C(C#N)=CC1=CC=C(OC)C=C1 HCHFRAXBELVCGG-UHFFFAOYSA-N 0.000 claims 1
- 101000609211 Homo sapiens Polyadenylate-binding protein 2 Proteins 0.000 claims 1
- 102100039427 Polyadenylate-binding protein 2 Human genes 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 108010056197 emerin Proteins 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 238000001476 gene delivery Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000036961 partial effect Effects 0.000 claims 1
- 230000003405 preventing effect Effects 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 230000004845 protein aggregation Effects 0.000 claims 1
- 230000002829 reductive effect Effects 0.000 claims 1
- 238000010187 selection method Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05077180 | 2005-09-23 | ||
| PCT/NL2006/000475 WO2007035092A2 (en) | 2005-09-23 | 2006-09-25 | Vhh for the diagnosis, prevention and treatment of diseases associated with protein aggregates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009508521A JP2009508521A (ja) | 2009-03-05 |
| JP2009508521A5 true JP2009508521A5 (enExample) | 2009-11-05 |
Family
ID=35700351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008532177A Pending JP2009508521A (ja) | 2005-09-23 | 2006-09-25 | タンパク凝集に関連する疾患の診断予防及び治療のためのｖｈｈ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20100323905A1 (enExample) |
| EP (1) | EP1934611A2 (enExample) |
| JP (1) | JP2009508521A (enExample) |
| AU (1) | AU2006292871A1 (enExample) |
| CA (1) | CA2622968A1 (enExample) |
| WO (1) | WO2007035092A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080107601A1 (en) * | 2004-10-13 | 2008-05-08 | Ablynx N.V. | Nanobodies Tm Against Amyloid-Beta and Polypeptides Comprising the Same for the Treatment of Degenerative Neural Diseases Such as Alzheimer's Disease |
| WO2010033913A1 (en) * | 2008-09-22 | 2010-03-25 | Icb International, Inc. | Antibodies, analogs and uses thereof |
| US20100136584A1 (en) * | 2008-09-22 | 2010-06-03 | Icb International, Inc. | Methods for using antibodies and analogs thereof |
| WO2011049449A1 (en) | 2009-10-22 | 2011-04-28 | University Of Twente | Vhh for application in tissue repair, organ regeneration, organ replacement and tissue engineering |
| EP2542579A1 (en) | 2010-03-03 | 2013-01-09 | Boehringer Ingelheim International GmbH | Biparatopic abeta binding polypeptides |
| MY167125A (en) | 2011-08-17 | 2018-08-13 | Glaxo Group Ltd | Modified proteins and peptides |
| US10112987B2 (en) | 2012-01-09 | 2018-10-30 | Icb International, Inc. | Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide |
| US10112988B2 (en) | 2012-01-09 | 2018-10-30 | Icb International, Inc. | Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide |
| EP2873679A1 (en) * | 2013-11-13 | 2015-05-20 | F.Hoffmann-La Roche Ag | Camelid single-domain antibody directed against amyloid bêta and methods for producing conjugates thereof |
| WO2018222587A1 (en) | 2017-05-30 | 2018-12-06 | The Regents Of The University Of California | NANOBODIES AGAINST CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) INHIBITORY FACTOR (Cif) |
| JP7122672B2 (ja) * | 2018-06-08 | 2022-08-22 | パナソニックＩｐマネジメント株式会社 | Ｖｈｈ抗体 |
| CN109206519B (zh) * | 2018-09-21 | 2021-12-03 | 成都阿帕克生物科技有限公司 | 一种抗尿素酶b亚单位的纳米抗体及核酸分子和应用 |
| EP4314076A4 (en) * | 2021-03-31 | 2025-07-09 | Kisoji Biotechnology Inc | BINDING AGENTS TARGETING TUMOR AND/OR IMMUNE CELLS |
| AU2024273077A1 (en) * | 2023-05-17 | 2025-11-13 | Odyssey Therapeutics, Inc. | Modified single-domain antibodies |
| WO2025133253A2 (en) * | 2023-12-22 | 2025-06-26 | Ablynx Nv | Protein-based conjugation carriers for intranuclear delivery |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1027439B1 (en) * | 1997-10-27 | 2010-03-17 | Bac Ip B.V. | Multivalent antigen-binding proteins |
| BR9907241A (pt) * | 1998-01-26 | 2000-10-17 | Unilever Nv | Biblioteca de expressão, processo para preparar a mesma, uso de uma fonte não imunizada de sequências de ácido nucleico, e, processos para preparar fragmentos de anticorpos e, para preparar um anticorpo |
| AUPR546801A0 (en) * | 2001-06-05 | 2001-06-28 | Commonwealth Scientific And Industrial Research Organisation | Recombinant antibodies |
| AR038568A1 (es) * | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
| FR2846667B1 (fr) * | 2002-11-06 | 2004-12-31 | Pasteur Institut | Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives |
| NZ540194A (en) * | 2002-11-08 | 2008-07-31 | Ablynx Nv | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| JP2006517789A (ja) * | 2003-01-10 | 2006-08-03 | アブリンクス エン．ヴェー． | 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用 |
| WO2005052002A2 (en) * | 2003-11-20 | 2005-06-09 | Massachusetts Institute Of Technology | Single-domain antibodies and uses thereof |
-
2006
- 2006-09-25 WO PCT/NL2006/000475 patent/WO2007035092A2/en not_active Ceased
- 2006-09-25 CA CA002622968A patent/CA2622968A1/en not_active Abandoned
- 2006-09-25 JP JP2008532177A patent/JP2009508521A/ja active Pending
- 2006-09-25 US US11/992,330 patent/US20100323905A1/en not_active Abandoned
- 2006-09-25 AU AU2006292871A patent/AU2006292871A1/en not_active Abandoned
- 2006-09-25 EP EP06799464A patent/EP1934611A2/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7221259B2 (ja) | 改変した抗体組成物、それを作製および使用する方法 | |
| JP2009508521A5 (enExample) | ||
| Müller et al. | Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain | |
| Omidfar et al. | Advances in phage display technology for drug discovery | |
| ES2641294T3 (es) | Nuevo anticuerpo para el diagnóstico y/o el pronóstico del cáncer | |
| US20170114149A1 (en) | Methods and compositions for in vivo non-covalent linking | |
| JP2014528695A5 (enExample) | ||
| IL273196B1 (en) | Claudin 6 antibodies and methods of cancer treatment | |
| JP2009517057A5 (enExample) | ||
| US20190031770A1 (en) | Intercalated single-chain variable fragments | |
| JP2013520174A5 (enExample) | ||
| JP2010516747A5 (enExample) | ||
| JP2015531768A5 (enExample) | ||
| JP6967507B2 (ja) | エピトープ選択のための新しい方法 | |
| CA2708074A1 (en) | Non-aggregating human vh domains | |
| EP3970798A1 (en) | Sars-cov-2-nanobodies | |
| JP2009511892A5 (enExample) | ||
| CN109563154A (zh) | 抗帕多瓦因子ix抗体 | |
| JP2005535562A5 (enExample) | ||
| JP2008533986A5 (enExample) | ||
| CN110642947B (zh) | 抗人cd147的单克隆抗体、表达载体、细胞株及其应用 | |
| JP4566911B2 (ja) | コバラミン分析方法 | |
| Gottlin et al. | Isolation of novel EGFR-specific VHH domains | |
| Hayes et al. | Overcoming antibody expression and screening limitations by smart design: applications to PSA immunoassay development | |
| JP2023159299A (ja) | α－シヌクレインプロトフィブリル結合抗体 |